Chargement des cours...
Prévisions
Aucune donnée d'analyste n'est disponible pour cette entreprise.
Actualités Accéder au fil d'actualités
OssDsign: revenue stagnates in Q2 2026, stock falls nearly 6%
OssDsign reported sequentially flat revenue of SEK 37.8m (approx. $4m) in Q2 2026, a decline of 18.7% year‑on‑year in SEK. Gross margin improved slightly to 92.1% and adjusted EBIT improved versus Q1, but investors reacted negatively and the stock fell 5.95% to $3.95, near the 52‑week low. Management cites a revenue plateau, is expanding the US sales team, and highlights product progress on MIS Catalyst, a hydrophilic strip version and a planned new indication for 2026. Seasonal headwinds are expected in Q3; the company expects gradual, non‑linear progress for the remainder of the year. » Plus sur de.investing.com
OssDsign records strong growth, shares fall sharply after earnings call
OssDsign reported organic growth of 35% in Q3 2025 and a gross margin of 95.6%, along with the best EBIT in the company’s history; revenues for the first nine months rose 54% to SEK 135 million. Despite the strong metrics, the stock fell 15.99% to $10.82 after the earnings call, partly due to missing EPS/revenue details and a $1.5 million revenue shift from Q2. Management plans to double the US sales team by 2026 and expects further product and market growth, but warned of non-linear growth and execution risks. » Plus sur de.investing.com
OssDsign AB reports strong Q2 growth and increases gross margin
OssDsign AB recorded organic growth of 73% year‑on‑year in the second quarter of 2025 and an improved gross margin of 96.8%, despite currency effects from a strong US dollar. The company raised CHF 160 million through a share issue, plans to expand its US sales team and aims for a 30% market share and over USD 400 million in revenue by 2028. Investor reaction was positive and the stock rose sharply in pre‑market trading. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | juin 2026 | |
|---|---|---|
| Chiffre d'affaires | 3,41M | 18,36% |
| Bénéfice brut | 3,14M | 22,30% |
| Bénéfice net | −1,03M | 37,52% |
| EBITDA | −1,07M | 72,15% |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 38,55M€ |
Nombre d'actions | 110,63M |
Plus haut/bas sur 52 semaines | 1,48€ - 0,30€ |
| Dividendes | Non |
Bêta | 0,65 |
Ratio P/E | −8,54 |
Ratio PEG | −5,07 |
Ratio P/B | 1,49 |
Ratio P/S | 2,61 |
Profil de l'entreprise
OssDsign AB (publ) entwickelt, produziert und vertreibt Implantate und Materialtechnologien für die Knochenregeneration in Schweden, Deutschland, den Vereinigten Staaten, dem Vereinigten Königreich, dem übrigen Europa und international. Zu den Produkten des Unternehmens gehören OSSDSIGN Cranial, eine Implantatlösung und entsprechendes Zubehör für die Rekonstruktion von Schädeldefekten bei Kranioplastik-Patienten, und OSSDSIGN Facial zur Behandlung posttraumatischer Skelettdeformationen und angeborener Skelettdefekte. Darüber hinaus bietet das Unternehmen OSSDSIGN Cranioplug zur Fixierung von Knochendeckeln und zur Abdeckung von Bohrlöchern sowie OssDsign Catalyst, ein nanosynthetisches Knochenersatzmaterial, das die Bildung von gesundem Knochengewebe anregt. Das Unternehmen wurde 2011 gegründet und hat seinen Hauptsitz in Uppsala, Schweden.
| Nom | OSSDSIGN AB Aktie |
| PDG | Mark Waugh |
| Siège social | Uppsala,
up Suède |
| Site web | |
| Introduction en bourse | 24/05/2019 |
| Employés | 32 |
Symboles boursiers
| Bourse | Symbole |
|---|---|
Sto | OSSD.ST |
Frankfurt | 5J6.F |
Stockholm | OSSD.ST |
München | 5J6.MU |
Découvrir des actifs
Les actionnaires de OSSDSIGN AB Aktie investissent également dans les actifs suivants
